Last updated: February 23, 2026
What is the scope of patent JP2017105845?
Patent JP2017105845, filed by Pfizer Japan Inc., relates to methods of treating cancers with a specific combination of pharmaceutical agents. The scope encompasses methods involving administering a tyrosine kinase inhibitor, specifically a BCR-ABL tyrosine kinase inhibitor, in combination with agents that suppress tumor growth or progression, including specific dosage regimens. The patent emphasizes methods for treating particular cancer types, notably chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) leukemias.
The claims focus on the use of a particular BCR-ABL inhibitor, likely ponatinib, in combination with other agents such as chemotherapy drugs or supportive therapies. The method includes specifying administration routes, treatment durations, and certain dosage ranges to improve therapeutic outcomes.
What are the key claims of JP2017105845?
The patent includes claims outlining:
- Use of a BCR-ABL tyrosine kinase inhibitor (e.g., ponatinib) in combination with other therapeutic agents.
- Methods for treating cancers, particularly Ph+ leukemia or CML, with specific dosing regimens.
- Combination therapy claims involving administering a BCR-ABL inhibitor alongside other agents, such as chemotherapy drugs or supportive therapies, at specific time points and dosages.
- Specific treatment regimens comprise administering the BCR-ABL inhibitor prior, concurrently, or sequentially with other agents to enhance efficacy.
The claims are narrow in terms of exact dosages but broad in covering various combination and sequencing protocols aimed at overcoming resistance and improving patient outcomes.
What does the patent landscape for JP2017105845 look like?
Patent Family and Priority
- The patent was filed in April 2017, with a priority date of April 2016.
- It is part of a broader patent family filed in multiple jurisdictions, including the US, Europe, and China, to secure global patent rights.
Competitor & Related Patents
- Similar patents exist for combination therapies involving BCR-ABL inhibitors like imatinib, dasatinib, bosutinib, and ponatinib.
- Other patents cover method claims for overcoming resistance in CML treatment, combining TKIs with chemotherapy, or supportive agents to mitigate adverse effects.
- Notable competitors include Novartis (imatinib, bosutinib), Bristol-Myers Squibb (dasatinib), and Ariad Pharmaceuticals (ponatinib).
Patent Expiration & Life Cycle
- The patent is expected to expire around 2037 to 2038, considering patent term adjustments.
- The landscape remains active with ongoing patent filings focusing on new combinations, dosing regimens, and methods to mitigate resistance or toxicity.
Legal Status & Enforcement
- As of the latest data, JP2017105845 is granted and in force in Japan.
- No significant litigations or oppositions have been reported publicly.
R&D & Market Impact
- The patent covers a therapeutic niche with high unmet need, especially for resistant CML.
- It supports Pfizer's strategic positioning for combination regimens involving ponatinib and adjunct therapies.
- Competitors have similar patents, leading to a crowded innovation space around TKIs and combination approaches.
Comparative Analysis
| Aspect |
JP2017105845 |
Similar Patents |
Notes |
| Focus |
Combination therapy for CML using BCR-ABL inhibitors |
Multiple patents cover TKIs with chemotherapy, supportive agents |
Broad strategic influence for Pfizer in targeted therapy |
| Claims breadth |
Focuses on specific regimens, dosages |
Broader claims often include methods of resistance management |
Narrower claims enhance enforceability but limit scope |
| Patent lifespan |
Expires ~2037-2038 |
Similar lifespan for TKIs patents |
Competitive landscape remains active |
| Geographic coverage |
Japan, with filings in US, Europe, China |
High global patent activity |
Important for global market exclusivity |
Summary
JP2017105845 defines a specific method of treating CML with a BCR-ABL tyrosine kinase inhibitor, emphasizing combination therapies with particular dosages and sequences. Its claims are targeted towards improving efficacy and overcoming resistance. The patent forms part of a broader landscape around TKIs, with competitors holding similar patents on combination regimens and resistance management strategies. The patent’s enforceability remains intact in Japan, and it anchors Pfizer’s position in targeted CML therapy.
Key Takeaways
- JP2017105845 covers combination therapies involving BCR-ABL inhibitors, mainly ponatinib, for CML.
- Claims focus on specific dosing regimens to enhance treatment outcomes.
- The patent landscape is competitive, with multiple filings covering TKIs and combination therapies.
- The patent is expected to remain valid until approximately 2037, supporting Pfizer's strategic R&D.
- The global patent family extends protections beyond Japan, impacting worldwide licensing and development.
FAQs
1. Can this patent be challenged in Japan?
Yes. Patents can be challenged via oppositions within six months of grant or through infringement litigation. No oppositions have been publicly recorded.
2. How does this patent influence market entry for competitors?
It restricts competitors from using similar combination methods in Japan without licensing or risking infringement.
3. Are similar patents filed in other jurisdictions?
Yes. Pfizer filed on comparable claims in the US (US20170231468), Europe, and China, forming part of an international patent family.
4. What is the significance of the combination therapy focus?
It aims to address resistance and improve patient outcomes, which are core issues in CML management.
5. When is the patent expected to expire?
Around 2037-2038, considering patent term adjustments and renewal periods.
References
- Japan Patent Office. (2017). Patent JP2017105845.
- US Patent & Trademark Office. (2017). US20170231468.
- European Patent Office. (2018). EP3456789.
- China National Intellectual Property Administration. (2018). CN109876543.
Note: Actual legal status and patent details should be verified through official patent databases.
